News & Updates
Filter by Specialty:
HIIT, resistance training boost wellbeing in chronic lymphocytic leukaemia
Patients with chronic lymphocytic leukaemia (CLL) may benefit from an exercise regimen consisting of high-intensity interval training (HIIT) and resistance training (RT), which could lead to better functional and general wellbeing, as well as a lower burden of lymphoma-specific symptoms, reports a recent study.
HIIT, resistance training boost wellbeing in chronic lymphocytic leukaemia
22 Sep 2022
POP: Delayed intake, missing one pill not a major reason for contraceptive failure
Delayed intake of a progestogen-only pill (POP) or missing one pill does not necessarily reduce its theoretical contraceptive protection, with little effect on cervical mucus and ovulation, as shown in a study.
POP: Delayed intake, missing one pill not a major reason for contraceptive failure
22 Sep 2022
Intensive weight-loss does not improve outcomes in obese NAFLD patients
An intensive weight-loss intervention has failed to substantially improve the treatment outcomes among obese patients with nonalcoholic fatty liver disease (NAFLD), reports a recent study.
Intensive weight-loss does not improve outcomes in obese NAFLD patients
22 Sep 2022
Schizophrenia imaging signatures tied to cognition, psychopathology, genetics
Researchers have recently reproduced two neuroanatomical signatures of schizophrenia, as well as shown their prevalence in youths and adults from the general population, reports a study.
Schizophrenia imaging signatures tied to cognition, psychopathology, genetics
22 Sep 2022
Inhaled IFN-β1a shows favourable signals for hospitalized COVID-19 patients
In the phase III SPRINTER trial, inhaled interferon-beta-1a (IFN-β1a) showed encouraging signals for preventing disease progression or death in hospitalized COVID-19 patients.
Inhaled IFN-β1a shows favourable signals for hospitalized COVID-19 patients
22 Sep 2022
Real-world HK study: Nirmatrelvir/ritonavir reduces hospitalizations in COVID-19 patients
The oral antiviral nirmatrelvir/ritonavir, but not molnupiravir, reduces the risk of hospitalization among community COVID-19 patients in Hong Kong, a real-world territory-wide retrospective cohort study has shown.
